Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Canada PM Carney strongly opposes US tariffs over Greenland
Trump links Greenland threat to Nobel Peace Prize snub, EU prepares to retaliate
Israel orders Gaza families to move in first forced evacuation since ceasefire
Rescue workers clearing Karachi inferno ruins, 63 missing feared dead
Blast kills seven at Chinese-run restaurant in Afghan capital
